ESC 365 - Extending the duration of dual antiplatelet therapy - Who could benefit?

Open Access

Extending the duration of dual antiplatelet therapy - Who could benefit?

Session: Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)

Topic: Thrombosis and platelets

Speaker: Professor D. Angiolillo (Jacksonville, US)

Sponsored by AstraZeneca

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Dominick Joseph Angiolillo

University of Florida College of Medicine – Jacksonville, Jacksonville (United States of America)

26 presentations

2 followers

4 more presentations in this session

Welcome and introduction - Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice.

Speaker: Professor P. Steg (Paris, FR)

Early initiation of dual anti-platelet therapy following an acute coronary syndrome: the clinical reality.

Speaker: Professor S. James (Uppsala, SE)

Discussion - Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice.

Speaker: Professor P. Steg (Paris, FR) Professor D. Angiolillo (Jacksonville, US) Professor S. James (Uppsala, SE) Professor R. Mehran (New York, US)

Summary and Close - Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice.

Speaker: Professor R. Mehran (New York, US)

Access the full session

Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)

Speakers: Professor D. Angiolillo, Professor P. Steg, Professor S. James, Professor P. Steg, Professor D. Angiolillo...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources